Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 3Myeloid 3Gynecologic 3Dermatologic 3Plasma cell 2Other neoplasm 2Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Colorectal Neoplasms 713Pancreatic Neoplasms 500Carcinoma, Hepatocellular 333Colonic Neoplasms 282Stomach Neoplasms 278Rectal Neoplasms 236Esophageal Neoplasms 198Neoplasms 194Liver Neoplasms 169Neoplasm Metastasis 164Carcinoma, Non-Small-Cell Lung 125Breast Neoplasms 111Cholangiocarcinoma 91Ovarian Neoplasms 87Lung Neoplasms 85Gastrointestinal Neoplasms 80Melanoma 76Gastrointestinal Stromal Tumors 68Adenocarcinoma Of Esophagus 64Adenocarcinoma 62Prostatic Neoplasms 59Biliary Tract Neoplasms 58Carcinoma, Renal Cell 56Sarcoma 54Head and Neck Neoplasms 54Urinary Bladder Neoplasms 51Gallbladder Neoplasms 49Barrett Esophagus 49Bile Duct Neoplasms 47Anus Neoplasms 47

Interventions

telaprevir 1peginterferon alfa-2a 1Ribavirin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Infections × Gastrointestinal × Clear all
NCT01821963 2020-09-24

Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)

M.D. Anderson Cancer Center

Phase 3 Terminated
1 enrolled 3 charts
Gastrointestinal

Hepatitis C, Carcinoma, Hepatocellular, Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡